CG Oncology(US:CGON)2024-05-09 12:10Filing Information This section details the administrative and legal information pertinent to the company's SEC filing Registrant Details This section provides the core identification details for CG Oncology, Inc. as filed with the SEC, including its incorporation state, commission file number, and principal executive offices - CG Oncology, Inc. is incorporated in Delaware with its principal executive offices located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA 926181 Securities and Status This section outlines the company's registered securities and its status as an emerging growth company, which impacts certain reporting requirements | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :--------------------------------------- | | Common Stock, par value $0.0001 per share | CGON | The Nasdaq Global Select Market | - The registrant, CG Oncology, Inc., is an emerging growth company3 Item 2.02 Results of Operations and Financial Condition This section reports the company's financial performance and condition for the specified period Quarterly Financial Results Announcement CG Oncology, Inc. announced its financial results for the quarter ended March 31, 2024, via a press release, which is attached as Exhibit 99.1. The information in this report, including the exhibit, is not considered 'filed' for certain legal purposes - On May 9, 2024, CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended March 31, 20244 - The press release (Exhibit 99.1) is incorporated by reference but the information in this Form 8-K, including Exhibit 99.1, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 193445 Item 9.01 Financial Statements and Exhibits This section lists all financial statements and supplementary exhibits included in the filing Exhibits Filed This section lists the documents officially filed as exhibits to this Form 8-K, primarily the press release detailing the financial results and the interactive data file | Exhibit No. | Description | | :------------ | :-------------------------------- | | 99.1 | Press Release Dated May 9, 2024 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | SIGNATURES This section provides official authorization and signatory details for the filed report Authorization and Signatory This section confirms the official authorization and signing of the Form 8-K by a duly authorized officer of CG Oncology, Inc - The report was signed on behalf of CG Oncology, Inc. by Corleen Roche, Chief Financial Officer, on May 9, 2024789